Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case report

被引：0
|
作者：
R. Trappe
A. Loew
P. Thuss-Patience
B. Dörken
H. Riess
机构：
[1] Charité Universitätsmedizin Berlin,Department of Hematology and Oncology
来源：
Annals of Hematology | 2006年 / 85卷
关键词：
Idiopathic Thrombocytopenic Purpura; Lupus Anticoagulant; High Platelet Count; Chronic Idiopathic Thrombocytopenic Purpura; Recurrent Fetal Loss;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：134 / 135
页数：1
相关论文
共 50 条
  • [21] Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
    Cooper, HL
    Healy, E
    Theaker, JM
    Friedmann, PS
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (04) : 366 - 368
  • [22] Anti-CD20 Antibody in Primary Sjogren's Syndrome Management
    Chen, Shiju
    Liu, Yuan
    Shi, Guixiu
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (06) : 535 - 541
  • [23] Anti-cd20 monoclonal antibody treatment (rituximab) in acute lymphoblastic leukemia
    Jándula, BM
    Nomdedeu, J
    Marín, P
    Muñoz, L
    Vivancos, P
    BONE MARROW TRANSPLANTATION, 2001, 27 : S92 - S92
  • [24] Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)
    Dupuy, A
    Viguier, M
    Bédane, C
    Cordoliani, F
    Blaise, S
    Aucouturier, F
    Bonnetblanc, JM
    Morel, P
    Dubertret, L
    Bachelez, H
    ARCHIVES OF DERMATOLOGY, 2004, 140 (01) : 91 - 96
  • [25] Treatment of Cutaneous Lymphoid Hyperplasia with the Monoclonal Anti-CD20 Antibody Rituximab
    Martin, Stephanie J.
    Duvic, Madeleine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (03): : 286 - 288
  • [26] Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
    Blase, Jennifer R.
    Frame, David
    Michniacki, Thomas F.
    Walkovich, Kelly
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [27] A fixed, low dose of anti-CD20 antibody (Rituximab) is an effective treatment for patients with chronic immune thrombocytopenia
    El-Najjar, I
    Rule, SAJ
    Nokes, TJC
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 79 - 80
  • [28] The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia
    Jacoub, J
    Mchlayeh, W
    Tabbara, I
    Dave, HP
    Siegel, R
    Schechter, GP
    BLOOD, 2004, 104 (11) : 74B - 74B
  • [29] A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
    Saleh, MN
    Gutheil, J
    Moore, M
    Bunch, PW
    Butler, J
    Kunkel, L
    Grillo-López, AJ
    LoBuglio, AF
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 99 - 103
  • [30] Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab
    Weitz, IC
    AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (02) : 138 - 141
12345